<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0026-1742</journal-id>
<journal-title><![CDATA[Revista de la Facultad de Medicina (México)]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Fac. Med. (Méx.)]]></abbrev-journal-title>
<issn>0026-1742</issn>
<publisher>
<publisher-name><![CDATA[Universidad Nacional Autónoma de México, Facultad de Medicina]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0026-17422014000600005</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Esclerosis múltiple: enfermedad neurológica de alto impacto social: de vuelta al antiguo tratamiento]]></article-title>
<article-title xml:lang="en"><![CDATA[Multiple sclerosis, neurological disease with high social impact: back to the old treatment]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Guadarrama-Ortiz]]></surname>
<given-names><![CDATA[Parménides]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Regalado Guerra]]></surname>
<given-names><![CDATA[Ximena]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Castillo-Rangel]]></surname>
<given-names><![CDATA[Carlos]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ángeles-Castellanos]]></surname>
<given-names><![CDATA[Manuel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,ISSSTE Hospital Regional 1° de Octubre ]]></institution>
<addr-line><![CDATA[ DF]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,UNAM Facultad de Medicina ]]></institution>
<addr-line><![CDATA[ DF]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,ISSSTE Hospital Regional 1° de Octubre ]]></institution>
<addr-line><![CDATA[ DF]]></addr-line>
<country>México</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Clínica de Neurotraumatología, SC  ]]></institution>
<addr-line><![CDATA[Nezahualcóyotl Estado de México]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2014</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2014</year>
</pub-date>
<volume>57</volume>
<numero>6</numero>
<fpage>5</fpage>
<lpage>10</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0026-17422014000600005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0026-17422014000600005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0026-17422014000600005&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen La esclerosis múltiple (EM) es una enfermedad inmune-inflamatoria y crónico-degenerativa, que afecta a personas jóvenes y tiene un alto impacto social por los costos directos e indirectos.  Objetivo: Regular el proceso neurodegenerativo a través de una adecuada modulación de los factores inflamatorios mediante el uso de metilprednisolona y la evaluación con estudios de resonancia magnética.  Pacientes y métodos: Pacientes mujeres que se encuentran entre la 1ª y 5ª década de la vida, con diagnóstico de EM, que se incluyeron por cumplir con los criterios diagnósticos de McDonald 2010 (sobre todo la diseminación en tiempo y espacio). Se les administraron bolos de metilprednisolona de manera regular, aun cuando no presentaran recaídas y se evaluaron con estudios de resonancia magnética (RM) anual, con un seguimiento de hasta 15 años.  Resultados: Se observa una marcada disminución de las lesiones en función del tiempo y la administración de los bolos de metilprednisolona, y entre los 3 y 10 años las lesiones desaparecen en su totalidad.  Conclusiones:  La administración de bolos de metilprednisolona de manera regular atenúa el proceso inflamatorio y el daño a la barrera hematoencefálica, y por lo tanto, coadyuva en la remielinización y previene la neurodegeneración.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Multiple sclerosis (MS) is a chronic inflammatory and immune-degenerative disease that affects young people and has a high social impact due to direct and indirect costs.  Objective: Regulate neurodegenerative process through a suitable modulation of inflammatory factors by using methylprednisolone and evaluation with Magnetic Resonance studies.  Patients and methods: Female patients between the 1st and 5th decade of life, with diagnosis of Multiple Sclerosis, were included in the study if they met the criteria of McDonal 2010 (specially space and time monitoring) methylprednisolone boluses were administered regularly, even when the patient had no relapses, and the patients were then evaluated with Magnetic Resonance per annum, with a follow-up of up to 15 years.  Results: There is a marked decrease of lesion in function of time and the bolus administration of methylprednisolone, and lesions disappeared entirely after 3 to 10 years of administration.  Conclusions: The regular bolus administration of methylprednisolone attenuates the inflammatory process and the damage to the blood brain barrier and thus contributes in preventing neurodegeneration and is coadyuvant in remyelination.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Enfermedad inmune-inflamatoria]]></kwd>
<kwd lng="es"><![CDATA[metilprednisolona]]></kwd>
<kwd lng="es"><![CDATA[resonancia magnética]]></kwd>
<kwd lng="es"><![CDATA[remielinización]]></kwd>
<kwd lng="es"><![CDATA[neurodegeneración]]></kwd>
<kwd lng="es"><![CDATA[neuroimagen]]></kwd>
<kwd lng="en"><![CDATA[Immune-inflammatory disease methylprednisolone]]></kwd>
<kwd lng="en"><![CDATA[magnetic resonance]]></kwd>
<kwd lng="en"><![CDATA[remyelination]]></kwd>
<kwd lng="en"><![CDATA[neurodegeneration]]></kwd>
<kwd lng="en"><![CDATA[neuroimagen]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Multiple Sclerosis in Latin America]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Corona]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Román]]></surname>
<given-names><![CDATA[GC]]></given-names>
</name>
</person-group>
<source><![CDATA[Neuroepidemiology]]></source>
<year>2006</year>
<volume>26</volume>
<page-range>1-3</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Multiple sclerosis, Diagnosis, management and prognosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tsang]]></surname>
<given-names><![CDATA[BK]]></given-names>
</name>
<name>
<surname><![CDATA[Macdonell]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Aust Fam Physician]]></source>
<year></year>
<volume>40</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>948-55</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Esclerosis múltiple en Latinoamérica]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rivera]]></surname>
<given-names><![CDATA[VM]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Española de Esclerosis Múltiple]]></source>
<year>2008</year>
<volume>9</volume>
<page-range>17-23</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Compston]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[McAlpine's multiple sclerosis]]></source>
<year>2006</year>
<publisher-loc><![CDATA[Philadelphia ]]></publisher-loc>
<publisher-name><![CDATA[Elsevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Life expectancy in patients attending multiple sclerosis clinics]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sadovnick]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Ebers]]></surname>
<given-names><![CDATA[GC]]></given-names>
</name>
<name>
<surname><![CDATA[Wilson]]></surname>
<given-names><![CDATA[RW]]></given-names>
</name>
<name>
<surname><![CDATA[Paty]]></surname>
<given-names><![CDATA[DW]]></given-names>
</name>
</person-group>
<source><![CDATA[Neurology]]></source>
<year>1992</year>
<volume>42</volume>
<page-range>991-4</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Trends in survival and cause of death in Danish patients with multiple sclerosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bronnum-Hansen]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Koch-Henriksen]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Stenager]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Brain]]></source>
<year>2004</year>
<volume>127</volume>
<page-range>844-50</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Esclerosis múltiple Epidemiología]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Corona-Vázquez]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Flores-Rivera]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Ed Med Panam]]></source>
<year>2010</year>
<page-range>7-25</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A descriptive profile of caregivers of older adults with MS and the assistance they provide]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Finlayson]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cho]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
</person-group>
<source><![CDATA[Disability and Rehabilitation]]></source>
<year>2008</year>
<volume>30</volume>
<numero>24</numero>
<issue>24</issue>
<page-range>1848-57</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Costs and quality of life in multiple sclerosis a cross-sectional study in the United States]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kobelt]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Berg]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Atherly]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Hadjimichael]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<source><![CDATA[Neurology]]></source>
<year>2006</year>
<volume>66</volume>
<page-range>1696-702</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Methylprednisolone inhibits IFN-? and IL-17 expression and production by cells infiltrating central nervous system in experimental autoimmune encephalomyelitis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Miljkovic]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Momcilovic]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Miljkovic]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Mostarica-Stojkovic]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Journal of Neuroinflammation]]></source>
<year>2009</year>
<volume>6</volume>
<numero>37</numero>
<issue>37</issue>
</nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Gray-Metter Injury in Multiple Sclerosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rudick]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bruce]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[N Engl J Med]]></source>
<year>2009</year>
<volume>361</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>1505-6</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Fingolimod for Multiple Sclerosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pelletier]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Hafler]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
</person-group>
<source><![CDATA[New England Journal of Medicine]]></source>
<year>2012</year>
<volume>366</volume>
<page-range>339-47</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Then-Bergh]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Kümpfel]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Schumann]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Held]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Schwan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Blazevic]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[BMC Neurology]]></source>
<year>2006</year>
<volume>9</volume>
<page-range>19</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Methylprednisolone therapy in multiple sclerosis a profile of adverse effects]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lyons]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
<name>
<surname><![CDATA[Newman]]></surname>
<given-names><![CDATA[PK]]></given-names>
</name>
<name>
<surname><![CDATA[Saunders]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Journal of Neurology, Neurosurgery, and Psychiatry]]></source>
<year>1988</year>
<volume>51</volume>
<page-range>285-7</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Development of autoimmune hepatitis type 1 after pulsed methylprednisolone therapy for multiple sclerosis A case report]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Takahashi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kanno]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Takahashi]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Sakamoto]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Monoe]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Saito]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<source><![CDATA[World J Gastroenterol]]></source>
<year>2008</year>
<volume>14</volume>
<numero>35</numero>
<issue>35</issue>
<page-range>5474-7</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Transtornos de la sustancia blanca]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Castillo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Neurorradiología]]></source>
<year>2004</year>
<page-range>70-4</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Comparison of MR pulse sequences in the detección of multiple sclerosis lesions]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yousry]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Filippi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Becker]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[AJNR Am J Neuroradiol]]></source>
<year>1997</year>
<volume>18</volume>
<page-range>959-63</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Horowitz]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Kaplan]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The ovoid lesion a new MR observation in patients with multiple sclerosis]]></article-title>
<collab>Grewe G y cols</collab>
<source><![CDATA[AJNR Am J Neuroradiol]]></source>
<year>1989</year>
<volume>10</volume>
<page-range>303-5</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Methylprednisolone in multiple sclerosis a comparison of oral with intravenous therapy al equivalent high dose]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alam]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Kyriakides]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Lawden]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Newman]]></surname>
<given-names><![CDATA[PK]]></given-names>
</name>
</person-group>
<source><![CDATA[Journal of Neurology, Neurosurgery and Psychiatry]]></source>
<year>1993</year>
<volume>56</volume>
<page-range>1219-20</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Elliott]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lindner]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Arthur]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Brain]]></source>
<year>2012</year>
<volume>135</volume>
<page-range>1819-33</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Katzman]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multiple Sclerosis]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Osborn]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
<name>
<surname><![CDATA[Blaser]]></surname>
<given-names><![CDATA[SI]]></given-names>
</name>
<name>
<surname><![CDATA[Salzman]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
<name>
<surname><![CDATA[Katzman]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
<name>
<surname><![CDATA[Provenzale]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Castillo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Diagnostic Imaging, Brain]]></source>
<year>2004</year>
<publisher-loc><![CDATA[Salt Lake City ]]></publisher-loc>
<publisher-name><![CDATA[Amyrsis]]></publisher-name>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
